Legend Biotech Corporation
LEGN
Classificação em ações
#4439
Legend Biotech Corporation, through its subsidiaries, operates as a... Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Preço da ação
$18.99
Valor de mercado
$3.51B
Variação (1 dia)
-0.11%
Variação (1 ano)
-42.21%
País
US
Negociar Legend Biotech Corporation (LEGN)
Categoria
Healthcare
Receita da Legend Biotech Corporation (LEGN)
Receita em Jun 2026 TTM: $1.27B
De acordo com os últimos relatórios financeiros da Legend Biotech Corporation, a receita atual da empresa (TTM) é $1.27B. Em 2023, a empresa obteve uma receita de $285.14M um aumento em relação a a receita do ano 2022, que foi de $117.01M. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Legend Biotech Corporation de 2017 a 2026
Receita no final de cada ano
| Ano | Receita | Alterar |
|---|---|---|
| 2026 (TTM) | $1.27B | 102.68% |
| 2024 | $627.24M | 119.97% |
| 2023 | $285.14M | 143.70% |
| 2022 | $117.01M | 70.00% |
| 2021 | $68.83M | -8.23% |
| 2020 | $75.00M | 21.36% |
| 2019 | $61.80M | 25.78% |
| 2018 | $49.13M | 108.24% |
| 2017 | $23.59M | 0.00% |
Receita de empresas similares ou concorrentes
| Empresa | Receita | Diferença de Receita | País |
|---|---|---|---|
| $12.62B | 893.02% |
US
|
|
| $2.23B | 75.25% |
US
|
|
| $15.74B | 1,138.44% |
AU
|
|
| $6.02B | 373.63% |
NL
|
|
| - | - |
CH
|
